Abstract
• Viral lineages that escape antibodies have changed the landscape of the pandemic. • SARS-CoV-2 specific T cells effectively protect against disease development. • Vaccine efficacy should be evaluated by its ability to protect from severe disease. • Inactivated SARS-CoV-2 vaccine induces a multi-protein specific T cell response. • The superior breadth of the vaccine T cell response could be a protective asset.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
